文献速递冠心病

无机硝酸盐降低急性冠脉综合征冠脉造影后对比剂肾病:NITRATE-CIN试验

Inorganic nitrate benefits contrast-induced nephropathy after coronary angiography for acute coronary syndromes: the NITRATE-CIN trial.
PubMed 文献 · Eur Heart J · 2024-01-01

NITRATE-CIN是一项双盲、随机、单中心、安慰剂对照试验,纳入640例因急性冠脉综合征接受冠脉造影的高危患者,随机接受每日一次硝酸钾(12 mmol)或安慰剂胶囊共5天。

要点

  • 5天口服无机硝酸盐显著降低高危ACS患者冠脉造影后对比剂肾病风险。
  • 无机硝酸盐组3个月eGFR改善、围术期心梗和1年MACE发生率均更低。
  • 该干预为短程、每日一次口服,具有临床转化潜力。

核心结论

  • 对于因ACS接受冠脉造影的肾损伤高危患者,5天每日一次无机硝酸盐可降低对比剂肾病、改善3个月肾脏结局并减少1年MACE。

研究设计与样本

  • NITRATE-CIN为双盲、随机、单中心、安慰剂对照试验,共随机640例ACS高危患者,1:1接受每日一次硝酸钾(12 mmol)或安慰剂(氯化钾)胶囊共5天。
  • 主要终点为对比剂肾病(KDIGO标准),次要终点包括3个月eGFR、围术期心肌梗死和12个月MACE;中位随访1.0年。

主要发现

  • 调整基线肌酐和糖尿病状态后,对比剂肾病风险仍显著降低(OR 0.21,95%CI 0.13-0.34)。
  • 3个月eGFR组间变化为5.17(95%CI 2.94-7.39),支持肾功能改善。

关键数值与推荐

  • 对比剂肾病采用KDIGO标准定义。
  • 无机硝酸盐干预为硝酸钾12 mmol每日一次,共5天。

临床怎么用

  • 对于因ACS行冠脉造影且存在肾损伤风险的患者,可考虑短期口服无机硝酸盐以降低对比剂肾病风险。
  • 该干预同时可能降低围术期心肌梗死和1年MACE,并改善3个月肾功能。

局限性

  • 本研究为单中心试验,外推性需进一步验证。
  • 中位随访仅1.0年,长期获益尚不明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Contrast-induced nephropathy (CIN), also known as contrast-associated acute kidney injury (CA-AKI) underlies a significant proportion of the morbidity and mortality following coronary angiographic procedures in high-risk patients and remains a significant unmet need. In pre-clinical studies inorganic nitrate, which is chemically reduced in vivo to nitric oxide, is renoprotective but this observation is yet to be translated clinically. In this study, the efficacy of inorganic nitrate in the prevention of CIN in high-risk patients presenting with acute coronary syndromes (ACS) is reported. METHODS: NITRATE-CIN is a double-blind, randomized, single-centre, placebo-controlled trial assessing efficacy of inorganic nitrate in CIN prevention in at-risk patients presenting with ACS. Patients were randomized 1:1 to once daily potassium nitrate (12 mmol) or placebo (potassium chloride) capsules for 5 days. The primary endpoint was CIN (KDIGO criteria). Secondary outcomes included kidney function [estimated glomerular filtration rate (eGFR)] at 3 months, rates of procedural myocardial infarction, and major adverse cardiac events (MACE) at 12 months. This study is registered with ClinicalTrials.gov: NCT03627130. RESULTS: Over 3 years, 640 patients were randomized with a median follow-up of 1.0 years, 319 received inorganic nitrate with 321 received placebo. The mean age of trial participants was 71.0 years, with 73.3% male and 75.2% Caucasian; 45.9% had diabetes, 56.0% had chronic kidney disease (eGFR <60 mL/min) and the mean Mehran score of the population was 10. Inorganic nitrate treatment significantly reduced CIN rates (9.1%) vs. placebo (30.5%, P < .001). This difference persisted after adjustment for baseline creatinine and diabetes status (odds ratio 0.21, 95% confidence interval 0.13-0.34). Secondary outcomes were improved with inorganic nitrate, with lower rates of procedural myocardial infarction (2.7% vs. 12.5%, P = .003), improved 3-month renal function (between-group change in eGFR 5.17, 95% CI 2.94-7.39) and reduced 1-year MACE (9.1% vs. 18.1%, P = .001) vs. placebo. CONCLUSIONS: In patients at risk of renal injury undergoing coronary angiography for ACS, a short (5 day) course of once-daily inorganic nitrate reduced CIN, improved kidney outcomes at 3 months, and MACE events at 1 year compared to placebo.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Jones, Beirne, Kelham, et al. Inorganic nitrate benefits contrast-induced nephropathy after coronary angiography for acute coronary syndromes: the NITRATE-CIN trial. Eur Heart J. 2024. PMID: 38513060. doi:10.1093/eurheartj/ehae100

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。